NCT06659068
Efficacy of Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
CD4+CD25+Foxp3+ regulatory T cells,
Timeframe: From enrollment to the end of the treatment at 12 weeks
IL-17/IL-10 ratio
Timeframe: From enrollment to the end of the treatment at 12 weeks
SLEDAI-2K score
Timeframe: From enrollment to the end of the treatment at 12 weeks
Arms and interventions
Seluang fish oil (Rasbora argyrotaenia) and SynbioticExperimental
Seluang fish oil (Rasbora argyrotaenia) and Synbiotic The patients were given a capsule containing seluang fish oil (Rasbora argyrotaenia) once a day and also synbiotic once a day
PlaceboPlacebo comparator
Placebo The patients were given placebo capsules of seluang fish oil (Rasbora argyrotaenia) and synbiotics once a day
Dietary supplements: Seluang fish oil (Rasbora argyrotaenia) and synbiotic, Placebo
Sites
1 site in 1 country
- Mohammad Hoesin General HospitalPalembang, South Sumatera, Indonesia